Recently, we have reported that low levels of CCDC6 associates with defects in DNA repair by Homologous Recombination (HR) affecting cells behaviour and cells sensitivity to PARP inhibitors treatment in lung and colon cancer models [16, 22]. This evidence concerns the gene PARP1 and colonic neoplasm.